Corrigendum to “The Utility of Ovotransferrin and Ovotransferrin-Derived Peptides as Possible Candidates in the Clinical Treatment of Cardiovascular Diseases”
Joint Authors
Peng, Hanhui
Fang, Jun
Chen, Shuang
Jiang, Hongmei
Wu, Xiaosong
Source
Oxidative Medicine and Cellular Longevity
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-2, 2 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-12-13
Country of Publication
Egypt
No. of Pages
2
Main Subjects
Abstract EN
In the article titled “The Utility of Ovotransferrin and Ovotransferrin-Derived Peptides as Possible Candidates in the Clinical Treatment of Cardiovascular Diseases” [1], there is a missing section that should be added between sections 4 and 5 as follows:
American Psychological Association (APA)
Chen, Shuang& Jiang, Hongmei& Peng, Hanhui& Wu, Xiaosong& Fang, Jun. 2018. Corrigendum to “The Utility of Ovotransferrin and Ovotransferrin-Derived Peptides as Possible Candidates in the Clinical Treatment of Cardiovascular Diseases”. Oxidative Medicine and Cellular Longevity،Vol. 2018, no. 2018, pp.1-2.
https://search.emarefa.net/detail/BIM-1210942
Modern Language Association (MLA)
Chen, Shuang…[et al.]. Corrigendum to “The Utility of Ovotransferrin and Ovotransferrin-Derived Peptides as Possible Candidates in the Clinical Treatment of Cardiovascular Diseases”. Oxidative Medicine and Cellular Longevity No. 2018 (2018), pp.1-2.
https://search.emarefa.net/detail/BIM-1210942
American Medical Association (AMA)
Chen, Shuang& Jiang, Hongmei& Peng, Hanhui& Wu, Xiaosong& Fang, Jun. Corrigendum to “The Utility of Ovotransferrin and Ovotransferrin-Derived Peptides as Possible Candidates in the Clinical Treatment of Cardiovascular Diseases”. Oxidative Medicine and Cellular Longevity. 2018. Vol. 2018, no. 2018, pp.1-2.
https://search.emarefa.net/detail/BIM-1210942
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1210942
